dabrafenib + pazopanib

Dabrafenib + pazopanib is an investigational oral combination therapy consisting of two small molecule kinase inhibitors. Dabrafenib is a selective inhibitor of mutant BRAF serine/threonine-protein kinase (most notably BRAF V600E), which blocks the MAPK pathway involved in cell proliferation and survival. Pazopanib is a multitargeted tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR-1, -2, -3), platelet-derived growth factor receptors (PDGFR-α and PDGFR-β), and c-Kit, thereby inhibiting angiogenesis and tumor blood vessel formation. This combination has been studied in phase I clinical trials for patients with advanced malignancies harboring BRAF mutations to address resistance mechanisms involving upregulation of VEGF or PDGF pathways. The regimen aims to enhance antitumor efficacy by simultaneously targeting both tumor cell proliferation (via BRAF inhibition) and tumor angiogenesis (via VEGF/PDGF inhibition)[1][2][8].

Other names

dabrafenib and pazopanib combination